Peptides / Tirzepatide
Tirzepatide
(Mounjaro, LY3298176)T1glp1clinical
Biomarker Effects
Fasting glucose
↓ moderate
Improves insulin sensitivity
HbA1c
↓ small
Improves glycemic control
Fasting insulin
↓ moderate
Reduces insulin resistance
HOMA-IR
↓ moderate
Improves insulin sensitivity
Triglycerides
↓ small
Improves lipid metabolism
HDL cholesterol
↑ small
Improves lipid profile
Dosing & Pharmacokinetics
Typical Dose2.5 mg
Frequencydaily
Routeclinician-directed
Half-Life5.0 days
Safety & Evidence
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes. Marketed as Mounjaro. Side effects include nausea, vomiting, and diarrhea.
Sources
Track Tirzepatide precisely in the Vivy app.
Your precision instrument awaits.
Download Vivy